BR112016007410A8 - conjugados de sn-38 de liberação lenta, formulações farmacêuticas e usos dos conjugados - Google Patents

conjugados de sn-38 de liberação lenta, formulações farmacêuticas e usos dos conjugados Download PDF

Info

Publication number
BR112016007410A8
BR112016007410A8 BR112016007410A BR112016007410A BR112016007410A8 BR 112016007410 A8 BR112016007410 A8 BR 112016007410A8 BR 112016007410 A BR112016007410 A BR 112016007410A BR 112016007410 A BR112016007410 A BR 112016007410A BR 112016007410 A8 BR112016007410 A8 BR 112016007410A8
Authority
BR
Brazil
Prior art keywords
conjugates
slow release
pharmaceutical formulations
glucuronate
abstract
Prior art date
Application number
BR112016007410A
Other languages
English (en)
Other versions
BR112016007410A2 (pt
BR112016007410B1 (pt
Inventor
l schneider Eric
Ashley Gary
Original Assignee
Prolynx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx Llc filed Critical Prolynx Llc
Publication of BR112016007410A2 publication Critical patent/BR112016007410A2/pt
Publication of BR112016007410A8 publication Critical patent/BR112016007410A8/pt
Publication of BR112016007410B1 publication Critical patent/BR112016007410B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

resumo liberação lenta de conjugados de sn 38 os conjugados de sn 38 que proporcionam taxas de liberação de droga óptimas e minimizar a formação do glucuronato correspondente são descritos. os conjugados de sn 38 liberados a partir de um polietileno glicol através de um mecanismo de eliminação ß.
BR112016007410-6A 2013-10-04 2014-10-03 Conjugados de sn-38 de liberação lenta, formulações farmacêuticas, métodos de preparo do referido conjugado e usos relacionados BR112016007410B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887111P 2013-10-04 2013-10-04
US61/887,111 2013-10-04
PCT/US2014/059146 WO2015051307A1 (en) 2013-10-04 2014-10-03 Slow-release conjugates of sn-38

Publications (3)

Publication Number Publication Date
BR112016007410A2 BR112016007410A2 (pt) 2017-08-01
BR112016007410A8 true BR112016007410A8 (pt) 2020-02-27
BR112016007410B1 BR112016007410B1 (pt) 2022-07-19

Family

ID=51871275

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007410-6A BR112016007410B1 (pt) 2013-10-04 2014-10-03 Conjugados de sn-38 de liberação lenta, formulações farmacêuticas, métodos de preparo do referido conjugado e usos relacionados

Country Status (14)

Country Link
US (2) US10016411B2 (pt)
EP (1) EP3052101B1 (pt)
JP (2) JP6473145B2 (pt)
KR (1) KR102320753B1 (pt)
CN (1) CN106061483B (pt)
AU (2) AU2014331591B2 (pt)
BR (1) BR112016007410B1 (pt)
CA (1) CA2925132C (pt)
DK (1) DK3052101T3 (pt)
ES (1) ES2759905T3 (pt)
MX (1) MX371201B (pt)
SG (2) SG10201811365RA (pt)
TW (1) TWI716342B (pt)
WO (1) WO2015051307A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201811365RA (en) * 2013-10-04 2019-02-27 Prolynx Llc Slow-release conjugates of sn-38
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
WO2018192550A1 (zh) 2017-04-21 2018-10-25 博瑞生物医药（苏州）股份有限公司 多臂靶向抗癌偶联物
US20200360545A1 (en) * 2018-01-12 2020-11-19 Prolynx Llc Protocol for minimizing toxicity of combination dosages and imaging agent for verification
KR20210072002A (ko) * 2018-09-17 2021-06-16 더 칠드런스 호스피탈 오브 필라델피아 폴리머 기반 거대분자 프로드러그
EP3946460A4 (en) * 2019-04-05 2023-03-29 Prolynx LLC IMPROVED CONJUGATION LINKERS
KR20220054368A (ko) * 2019-08-28 2022-05-02 프로린크스 엘엘시 Dna 손상 반응의 컨쥬게이션된 억제제
WO2022064052A1 (en) 2020-09-28 2022-03-31 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Peptidic conjugates of sn38 useful in the treatment of cancer
US11976196B2 (en) * 2021-04-14 2024-05-07 Cambridge Crops, Inc. Silk packaging applications
AU2023242296A1 (en) 2022-03-28 2024-09-19 Gate2Brain, S.L. Peptidic water-soluble delivery system of anticancer drugs

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
EP1534823A4 (en) * 2002-07-12 2008-12-31 Biomarin Pharm Inc USE OF ISOCYANATE BINDING AGENTS FOR PRODUCING BIOPOLYMER-HYDRAULIC ACTIVE SUBSTANCE CONJUGATES
US7495099B2 (en) 2002-10-31 2009-02-24 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
EP2626083A1 (en) * 2003-09-17 2013-08-14 Nektar Therapeutics Multi-arm polymer prodrugs
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
RU2009114154A (ru) * 2006-09-15 2010-10-20 Энзон Фармасьютикалз, Инк. (Us) Полимерные пролекарства с направленной доставкой, содержащие полифункциональные линкеры
KR20110075029A (ko) * 2008-10-21 2011-07-05 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
CA2743907A1 (en) 2008-11-18 2010-05-27 Baxter International Inc. Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample
CN102448469A (zh) 2009-05-28 2012-05-09 摩萨纳医疗有限公司 包括具有可变的释放速率的连接物的聚缩醛(酮)-药物共轭物
DK2501413T3 (da) * 2009-11-18 2019-06-11 Nektar Therapeutics Syre-saltformer af polymermedikamentkonjugater
CN103025165B (zh) * 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释
WO2011140376A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
JP2012000072A (ja) * 2010-06-18 2012-01-05 Japan Health Science Foundation 新規な抗フィブリン抗体
WO2012029076A2 (en) 2010-08-30 2012-03-08 Sun Pharma Advanced Research Company Ltd. Stable pharmaceutical composition
JP5899241B2 (ja) * 2010-12-21 2016-04-06 ネクター セラピューティクス ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
SG10201811365RA (en) * 2013-10-04 2019-02-27 Prolynx Llc Slow-release conjugates of sn-38

Also Published As

Publication number Publication date
DK3052101T3 (da) 2019-12-16
AU2014331591B2 (en) 2018-08-16
US20180289695A1 (en) 2018-10-11
CN106061483B (zh) 2021-01-08
MX371201B (es) 2020-01-22
AU2014331591A1 (en) 2016-05-19
TWI716342B (zh) 2021-01-21
US10342792B2 (en) 2019-07-09
JP2016531895A (ja) 2016-10-13
WO2015051307A1 (en) 2015-04-09
ES2759905T3 (es) 2020-05-12
EP3052101A1 (en) 2016-08-10
JP6473145B2 (ja) 2019-02-20
JP2019104739A (ja) 2019-06-27
CN106061483A (zh) 2016-10-26
CA2925132A1 (en) 2015-04-09
KR20160065203A (ko) 2016-06-08
SG10201811365RA (en) 2019-02-27
JP6842479B2 (ja) 2021-03-17
AU2018256608A1 (en) 2018-11-22
BR112016007410A2 (pt) 2017-08-01
KR102320753B1 (ko) 2021-11-02
US10016411B2 (en) 2018-07-10
TW201601759A (zh) 2016-01-16
US20160243106A1 (en) 2016-08-25
SG11201602258WA (en) 2016-04-28
MX2016004299A (es) 2016-10-04
BR112016007410B1 (pt) 2022-07-19
CA2925132C (en) 2021-11-30
EP3052101B1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
BR112016007410A8 (pt) conjugados de sn-38 de liberação lenta, formulações farmacêuticas e usos dos conjugados
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
MY191574A (en) Pharmaceutical compositions comprising meloxicam
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
BR112015006731A2 (pt) combinações e usos das mesmas
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
BR112017028552A2 (pt) partículas e conjugados direcionados e formulações dos mesmos
EA201690874A1 (ru) Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением
CL2016000148A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
EP3701937A4 (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING A NON-STEROID ANTI-INFLAMMATORY DERIVATIVE
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
BR112018007673A2 (pt) ?análogos de epotilona, métodos de síntese, métodos de tratamento e conjugados de fármaco dos mesmos?
DK3453390T3 (da) Farmaceutisk sammensætning indeholdende polymeriseret lægemiddel
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
EA201400444A1 (ru) Производные 2-оксопиперидинила

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4745 (2006.01), A61K 9/00 (2006.01), A61K

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/10/2014, OBSERVADAS AS CONDICOES LEGAIS